Literature DB >> 10940222

Solution structures in aqueous SDS micelles of two amyloid beta peptides of A beta(1-28) mutated at the alpha-secretase cleavage site (K16E, K16F).

S A Poulsen1, A A Watson, D P Fairlie, D J Craik.   

Abstract

NMRsolution structures are reported for two mutants (K16E, K16F) of the soluble amyloid beta peptide Abeta(1-28). The structural effects of these mutations of a positively charged residue to anionic and hydrophobic residues at the alpha-secretase cleavage site (Lys16-Leu17) were examined in the membrane-simulating solvent aqueous SDS micelles. Overall the three-dimensional structures were similar to that for the native Abeta(1-28) sequence in that they contained an unstructured N-terminus and a helical C-terminus. These structural elements are similar to those seen in the corresponding regions of full-length Abeta peptides Abeta(1-40) and Abeta(1-42), showing that the shorter peptides are valid model systems. The K16E mutation, which might be expected to stabilize the macrodipole of the helix, slightly increased the helix length (residues 13-24) relative to the K16F mutation, which shortened the helix to between residues 16 and 24. The observed sequence-dependent control over conformation in this region provides an insight into possible conformational switching roles of mutations in the amyloid precursor protein from which Abeta peptides are derived. In addition, if conformational transitions from helix to random coil to sheet precede aggregation of Abeta peptides in vivo, as they do in vitro, the conformation-inducing effects of mutations at Lys16 may also influence aggregation and fibril formation. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940222     DOI: 10.1006/jsbi.2000.4267

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  6 in total

1.  Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, an antibody specific for the Abeta peptides associated with Alzheimer's disease.

Authors:  Kwok S Wun; Luke A Miles; Gabriela A N Crespi; Kaye Wycherley; David B Ascher; Kevin J Barnham; Roberto Cappai; Konrad Beyreuther; Colin L Masters; Michael W Parker; William J McKinstry
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-04-30

2.  Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor?

Authors:  Andrew J Beel; Charles K Mobley; Hak Jun Kim; Fang Tian; Arina Hadziselimovic; Bing Jap; James H Prestegard; Charles R Sanders
Journal:  Biochemistry       Date:  2008-08-15       Impact factor: 3.162

3.  Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.

Authors:  Gabriela A N Crespi; Stefan J Hermans; Michael W Parker; Luke A Miles
Journal:  Sci Rep       Date:  2015-04-16       Impact factor: 4.379

Review 4.  Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease.

Authors:  Touqeer Ahmed; Saadia Zahid; Aamra Mahboob; Syeda Mehpara Farhat
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

5.  Weak glycolipid binding of a microdomain-tracer peptide correlates with aggregation and slow diffusion on cell membranes.

Authors:  Tim Lauterbach; Manoj Manna; Maria Ruhnow; Yudi Wisantoso; Yaofeng Wang; Artur Matysik; Kamila Oglęcka; Yuguang Mu; Susana Geifman-Shochat; Thorsten Wohland; Rachel Kraut
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

Review 6.  Alzheimer's disease--a panorama glimpse.

Authors:  Li Na Zhao; Lanyuan Lu; Lock Yue Chew; Yuguang Mu
Journal:  Int J Mol Sci       Date:  2014-07-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.